The Washington State attorney general\u2019s office appeared alongside lawyers representing cancer patients on Thursday, telling a federal appeals panel that people in end-of-life care deserve legal access to psilocybin\u2014the main psychoactive compound in psychedelic mushrooms\u2014under state and federal right-to-try laws.<\/p>\n
\u201cIt is entirely consistent with the purpose and language of the state and federal right-to-try laws to include any controlled substances that have completed Phase 1 trials, including Schedule I controlled substances,\u201d Washington Deputy Solicitor General Peter B. Gonick said in oral argument before a three-judge panel of the U.S. Court of Appeals for the Ninth Circuit, referring to a category of illegal drugs that includes psilocybin. \u201cIt\u2019s entirely inconsistent with the right-to-try laws to prevent patient access to these treatments.\u201d<\/p>\n
Congress and 41 U.S. states have adopted right-to-try (RTT) laws, which allow patients with terminal conditions to try investigational medications that have not been approved for general use. But in the case before the Ninth Circuit, two patients and a Seattle-based palliative care clinic, the Advanced Integrated Medical Science (AIMS) Institute, say the U.S. Drug Enforcement Administration (DEA) is standing in their way.<\/p>\n
The group sued DEA in March<\/a>, after the agency replied to a request for guidance from the clinic\u2019s co-director, Dr. Sunil Aggarwal. DEA asserted that the only way for the AIMS Institute to dispense psilocybin legally would be to obtain a federal research permit, which \u201cwould not be applicable to Dr. Aggarwal at this time.\u201d<\/p>\n Out of the gate at oral argument Thursday, judges initially expressed skepticism over whether they even had jurisdiction to hear the case at this point. DEA maintains its letter to the clinic was simply an informal opinion, not a reviewable decision.<\/p>\n \u201cIsn\u2019t that the beginning and the and of this case?\u201d Judge Ryan D. Nelson, an appointee of President Donald Trump, interjected barely 10 seconds after arguments began. \u201cThey wrote, seeking instructions on how to proceed\u2026 So if they sought instructions, how can a response for instructions ever be a final order?\u201d<\/p>\n Attorney Matthew Zorn, who represented the patients and clinic suing DEA at Thursday\u2019s oral arguments<\/a>, replied that the agency\u2019s response effectively gave them no options. \u201cThat response was: There is no process,\u201d Zorn said. \u201cIf they had identified a process, we would have used that process. Because the agency said, \u2018There is nothing for you to use,\u2019 there is nowhere for us to go.\u201d<\/p>\n For several minutes, judges on the panel\u2014which also included Trump appointee Judge Mark J. Bennett and Judge Sandra Segal Ikuta, appointed by President George W. Bush\u2014peppered Zorn with questions about whether DEA\u2019s reply was even reviewable under court precedent.<\/p>\n \u201cYou didn\u2019t ask [DEA] for an interpretive rule,\u201d Nelson said.<\/p>\n \u201cYou asked for guidance,\u201d agreed Ikuta.<\/p>\n \u201cWe didn\u2019t ask for it,\u201d Zorn told Nelson, \u201cbut that\u2019s what we got.\u201d<\/p>\n \u201cI agree if that\u2019s what you got the case might be different,\u201d Nelson answered with an audible chuckle.<\/p>\n Though Zorn\u2019s allotted time ended with some questions from judges unanswered, the panel\u2019s mood appeared to change as the attorney dissected a federal court decision out of the Eastern District of Tennessee, which Nelson raised as a challenge. Zorn explained how he thought that decision was made in error, running contrary to a U.S. Supreme Court ruling dealing with the U.S. Environmental Protection Agency.<\/p>\n \u201cThis is crystal clear. I do think that court erred,\u201d Zorn argued, as Nelson nodded his head.<\/p>\n Speaking after Zorn, Gonick, the Washington State deputy solicitor general, offered arguments on behalf of that state. Lawmakers there, where the AIMS Institute is located, passed a state right-to-try law unanimously in 2017, allowing terminally ill patients access to treatments that have passed Phase 1 of the U.S. Food and Drug Administration (FDA)\u2019s approval process.<\/p>\n \u201cThe average time, Phase 1 to FDA approval, is seven to 10 years,\u201d Gonick told judges, \u201cand Congress and 41 states determined that was just too long for some patients suffering life-threatening illnesses.\u201d<\/p>\n The laws express the recognition that some patients \u201cmay not have time to wait for FDA approval to receive treatments,\u201d he added, \u201ctreatments that currently have \u2018no accepted medical use,\u2019 as the drugs in Schedule I have been designated\u201d under the federal Controlled Substances Act (CSA).<\/p>\n The DEA attorney, Department of Justice (DOJ) appellate lawyer Thomas Pulham, argued the\u00a0case itself should be dismissed because the court lacks jurisdiction. If the agency had explicitly rejected the clinic\u2019s application for a research permit, he said, only then could that decision be appealed.<\/p>\n \u201cDEA\u2019s action is not subject to judicial review, because it neither reflects the consummation of a decision-making process nor results in any legal consequences,\u201d Pulham said. \u201cIt was an informal response to a request for assistance from a member of a regulated community that did nothing more than provide the agency\u2019s view on existing law.\u201d<\/p>\n The agency also argued to the court in a June filing that loosening restrictions on psilocybin could fuel the illegal drug trade<\/a>.<\/p>\n Judges were skeptical of the government\u2019s stance, however, and repeatedly asked Pulham how the clinic and its patients should have proceeded, in DEA\u2019s view.<\/p>\n \u201cWhat about under the Right to Try law, though?\u201d asked Judge Ikuta. \u201cIs there a pathway where they could apply under the Right to Try Act?\u201d<\/p>\n No, the lawyer for DEA replied. \u201cAs the agency indicated in its letter, there\u2019s no procedure available under the Right to Try Act, because the Right to Try Act does not provide the agency any authority to waive the requirements of the Controlled Substances Act.\u201d<\/p>\n Pulham argued that if the AIMS Institute and its patients were to proceed with psilocybin therapy and face enforcement action by the DEA, they could raise their right-to-try arguments at that point.<\/p>\n \u201cUsually we don\u2019t require a party to go and subject themselves to liability in order to appeal,\u201d interrupted Judge Nelson. \u201cIt sounds like there might actually be some legal consequences here. I mean, it is prohibiting them from doing what they want to do, and it\u2019s subjecting them to enforcement action if they were to go forward.\u201d<\/p>\n \u201cThe letter does not do that,\u201d Pulham stressed. \u201cThe Controlled Substances Act does that.\u201d<\/p>\n \u201cWhen Congress passed the Controlled Substances Act, it designated psilocybin as a controlled, Schedule I controlled substance based on findings that the drug had a high potential for abuse and no accepted medical use,\u201d he continued. \u201cThat determination made psilocybin, in the Supreme Court\u2019s words, contraband for all purposes, except for one exception, which is research.\u201d<\/p>\n In his few remaining minutes of argument for rebuttal, Zorn emphasized that his clients are merely asking DEA to explain how clinicians and patients should move forward under right-to-try laws. \u201cThe agency has said it has no authority to give us what we\u2019re asking for, which is a process to apply for a waiver and exemption to vindicate right-to-try use,\u201d he said, \u201cwhich is very different from research use.\u201d He also noted that DEA has accommodated some ceremonial use of controlled substances under the Religious Freedom Restoration Act (RFRA), which is also not explicitly exempt from the CSA.<\/p>\n Zorn\u2019s colleagues and clients cheered Zorn\u2019s performance and said they hope it helps persuade the three-judge panel to rule in their favor.<\/p>\n \u201cI am so grateful for such a landmark day in a higher court for us, in which our legal team was able to help in the slow chipping away of the DEA\u2013CSA industrial complex status quo that stymies public health, healthcare, religious freedom, and the needs of the seriously ill,\u201d Aggarwal, co-director of the AIMS Institute, told Marijuana Moment. \u201cNow we await a swift and just ruling.\u201d<\/p>\n Attorney Kathryn Tucker, who also represents AIMS and the patients, said that the panel \u201cappeared over the course of the argument to appreciate that the agency had left no avenue open and hence the matter was properly before the court.\u201d<\/p>\n \u201cThe sense I had watching the arguments was that the judges wanted to know how DEA would accommodate RTT and enable access for therapeutic use,\u201d she said. \u201cDOJ had no good answer to that.\u201d<\/p>\n As AIMS and its patients challenge DEA\u2019s restrictions on therapeutic psilocybin for end-of-life care, jurisdictions across the country are increasingly removing or reducing penalties around drug possession and consumption, especially when it comes to psychedelics.<\/p>\n A task force in Seattle, where AIMS is located, recently called on the City Council, as well as state lawmakers and other municipalities, to decriminalize all drugs as a way to curb overdose deaths<\/a>. The group\u2019s report also notes the potential shown by psychedelics in particular for treating various mental health disorders.<\/p>\n At the state level, Washington lawmakers reduced the state\u2019s felony charge for drug possession to a misdemeanor<\/a>\u00a0earlier this year and earmarked more money for treatment following a state Supreme Court decision that\u00a0overturned the states felony law against drug possession completely<\/a>.<\/p>\n Not far north, in Canada, the country\u2019s Health Ministry has granted case-by-case approval for some patients<\/a>, as well as health care professionals<\/a>, to access psilocybin for therapeutic use.<\/p>\n In California, meanwhile, a Senate-passed bill to\u00a0legalize possession of a wide range of psychedelics advanced through several Assembly committees this session, but it will not move further this year<\/a> following a decision by the sponsor that more time is needed to build the case for the reform and solidify its chances of being enacted.<\/p>\n California psychedelics activists also recently\u00a0filed a petition for the 2022 ballot<\/a>\u00a0to make the state the first in the nation to legalize psilocybin mushrooms for any use. Oakland<\/a>\u00a0and\u00a0Santa Cruz<\/a>\u00a0have already enacted psychedelics decriminalization. The state\u2019s nonpartisan Legislation Analyst\u2019s Office said this week that the statewide ballot measure could save the state tens of millions of dollars<\/a>\u00a0in annual enforcement costs.<\/p>\n In Michigan, the Ann ArborCity Council\u00a0approved the policy change last year<\/a>\u2014and local lawmakers recently passed a resolution to officially designate September as Entheogenic Plants and Fungi Awareness Month<\/a>.<\/p>\n In Massachusetts, cities that have enacted the policy change include\u00a0Northampton<\/a>,\u00a0Somerville<\/a>\u00a0and\u00a0Cambridge<\/a>.<\/p>\n In Denver the first city to adopt psilocybin reform, activists are now pushing to expand the psilocybin decriminalization policy<\/a> to cover gifting and communal use of the substance.<\/p>\n The governor of Connecticut recently signed legislation recently that includes language requiring the state to carry out\u00a0a study into the therapeutic potential of psilocybin mushrooms<\/a>, meanwhile, and Texas recently enacted a bill to require the state\u00a0study the medical benefits of psychedelics for military veterans<\/a>.<\/p>\n A New York lawmaker introduced a bill in June that would require the state to establish an institute to similarly\u00a0research the medical value of psychedelics<\/a>.<\/p>\n In Oakland, the first city where a city council voted to broadly deprioritize criminalization of entheogenic substances, lawmakers\u00a0approved a follow-up resolution<\/a>\u00a0in December that calls for the policy change to be adopted statewide and for local jurisdictions to be allowed to permit healing ceremonies where people could use psychedelics.<\/p>\n After Ann Arbor legislators passed a decriminalization resolution last year, a county prosecutor recently announced\u00a0that his office will not be pursuing charges<\/a>\u00a0over possessing entheogenic plants and fungi\u2014\u201cregardless of the amount at issue.\u201d<\/p>\n The Aspen, Colorado City Council\u00a0discussed the therapeutic potential of psychedelics<\/a>\u00a0like psilocybin and proposals to decriminalize such substances at a meeting in May. But members said, as it stands, enacting a reform would be more better handled at the state level while entheogens remain strictly federally controlled.<\/p>\n Activists in Portland, Oregon, meanwhile, are mounting\u00a0a push to have local lawmakers pass a resolution<\/a>\u00a0decriminalizing the cultivation, gifting and ceremonial use of a wide range of psychedelics.<\/p>\n In a setback for advocates, the U.S. House of Representatives recently voted against a proposal from Rep. Alexandria Ocasio-Cortez (D-NY) that would have removed a spending bill rider<\/a>\u00a0that advocates say has restricted federal funds for research into Schedule I drugs, including psychedelics such as psilocybin, MDMA and ibogaine. However, it picked up considerably more votes this round than\u00a0when the congresswoman first introduced it<\/a>\u00a0in 2019.<\/p>\n Report provisions of separate, House-passed spending legislation also touch on the need to\u00a0expand cannabis and psychedelics research<\/a>. The panel urged the National Institute On Drug Abuse (NIDA) to support expanded marijuana studies, for example<\/p>\n It further says that federal health agencies should\u00a0pursue research into the therapeutic potential of psychedelics<\/a>\u00a0for military veterans suffering from a host of mental health conditions.<\/p>\n When it comes to broader drug policy reform, Oregon voters also approved an initiative in November to\u00a0decriminalize possession of all drugs<\/a>. This year, the Maine House of Representatives\u00a0passed a drug decriminalization bill<\/a>, but it later\u00a0died in the Senate<\/a>.<\/p>\n In May, lawmakers in Congress filed the\u00a0first-ever legislation to federally decriminalize possession<\/a>\u00a0of illicit substances.<\/p>\n DEA Proposes Massive Increase In Marijuana And Psilocybin Production For Research To Develop FDA-Approved Medicines<\/a><\/p>\n<\/blockquote>\n\n Photo courtesy of Wikimedia\/Mushroom Observer<\/a><\/p>\n The post Washington Officials Join Cancer Patients In Federal Court Argument Pushing DEA To Allow Psilocybin Access<\/a> appeared first on Marijuana Moment<\/a>.<\/p>\n
The Washington State attorney general\u2019s office appeared alongside lawyers representing cancer patients on Thursday, telling a federal appeals panel that people in end-of-life care deserve legal access to psilocybin\u2014the main psychoactive compound in psychedelic mushrooms\u2014under state and federal right-to-try laws. \u201cIt is entirely consistent with the purpose and language ofContinue Reading<\/a><\/span><\/p>\n","protected":false},"author":24,"featured_media":0,"comment_status":"false","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[18,81,126],"tags":[],"_links":{"self":[{"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/posts\/49780"}],"collection":[{"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/comments?post=49780"}],"version-history":[{"count":1,"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/posts\/49780\/revisions"}],"predecessor-version":[{"id":49781,"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/posts\/49780\/revisions\/49781"}],"wp:attachment":[{"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/media?parent=49780"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/categories?post=49780"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cannabiscultivatornews.com\/home\/index.php\/wp-json\/wp\/v2\/tags?post=49780"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n
\n
\nRead More: Washington Officials Join Cancer Patients In Federal Court Argument Pushing DEA To Allow Psilocybin Access<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"